Sun Pharmaceutical Industries is garnering investor attention following the U.S. Food and Drug Administration’s (USFDA) approval of its next-generation BLU-U® Blue Light Photodynamic Therapy (PDT) device. This advanced device is designed to treat actinic keratosis (AK), a precancerous skin condition resulting from prolonged sun exposure.

The newly approved BLU-U® device incorporates light-emitting diode (LED) technology, replacing the older fluorescent-tube-based model. This upgrade offers a more compact design, a flexible five-panel configuration, and optimized LED arrangement, enhancing patient comfort and usability. The device is used in conjunction with LEVULAN® KERASTICK®, a topical solution containing aminolevulinic acid, to target and treat minimally to moderately thick AK lesions on the face, scalp, and upper extremities .

The USFDA granted approval under its Real-Time Review Program, reflecting the robustness of Sun Pharma’s submission and the agency’s commitment to expediting access to innovative treatments . This milestone is expected to bolster Sun Pharma’s presence in the dermatology segment and strengthen its medical device offerings .

As of 10:11 AM IST on May 19, 2025, Sun Pharma’s shares are anticipated to respond positively to this development, reflecting investor optimism about the company’s expanded dermatological portfolio and potential market growth.